| 肿瘤血管生成抑制剂临床应用进展 |
| |
| 引用本文： | 陆宇. 肿瘤血管生成抑制剂临床应用进展[J]. 上海师范大学学报(自然科学版), 2018, 47(1): 132-138 |
| |
| 作者姓名： | 陆宇 |
| |
| 作者单位： | 南京天易生物科技有限公司; |
| |
| 基金项目： | 江苏省自然科学基金（BK20130106） |
| |
| 摘 要： | 血管生成抑制剂已被证明是一类有效的肿瘤治疗药物.概述了从单靶点、多靶点,到广谱血管生成抑制剂在临床上的应用;介绍了单克隆抗体、小分子和内源性的血管生成抑制剂及其相应靶点,讨论了新的靶点及有前景的新型血管生成抑制剂,希望为未来临床治疗提供切实的帮助.
|
| 关 键 词： | 肿瘤 血管生成 血管生成抑制剂 |
| 收稿时间： | 2016-06-03 |
Current clinical application progress in angiogenesis inhibitors |
| |
| Lu Yu. Current clinical application progress in angiogenesis inhibitors[J]. Journal of Shanghai Normal University(Natural Sciences), 2018, 47(1): 132-138 |
| |
| Authors: | Lu Yu |
| |
| Affiliation: | Nanjing Tianyi Bioscience Co. Ltd., Nanjing 210061, China |
| |
| Abstract: | Inhibition of angiogenesis is an established modality of cancer treatment.We summarized angiogenesis inhibitors of three modalities:single-target,multi-target and broad-spectrum agents.We discussed the clinical efficacy of monoclonal antibodies,small molecules,endogenous angiogenesis inhibitors and their molecular targets.The promising targets and antiangiogenic treatments were discussed as well.This reviewing article may offer practical help for cancer therapy in the future. |
| |
| Keywords: | tumor angiogenesis angiogenesis inhibitors |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《上海师范大学学报(自然科学版)》浏览原始摘要信息 |
|
点击此处可从《上海师范大学学报(自然科学版)》下载全文 |
